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Abstract
Rho-family GTPases like RhoA and Rac-1 are potent regulators of cellular signaling that control gene expression,
migration and inflammation. Activation of Rho-GTPases has been linked to podocyte dysfunction, a feature of chronic
kidney diseases (CKD). We investigated the effect of Rac-1 and Rho kinase (ROCK) inhibition on progressive renal
failure in mice and studied the underlying mechanisms in podocytes. SV129 mice were subjected to 5/6-nephrectomy
which resulted in arterial hypertension and albuminuria. Subgroups of animals were treated with the Rac-1 inhibitor
EHT1846, the ROCK inhibitor SAR407899 and the ACE inhibitor Ramipril. Only Ramipril reduced hypertension. In
contrast, all inhibitors markedly attenuated albumin excretion as well as glomerular and tubulo-interstitial damage.
The combination of SAR407899 and Ramipril was more effective in preventing albuminuria than Ramipril alone. To
study the involved mechanisms, podocytes were cultured from SV129 mice and exposed to static stretch in the
Flexcell device. This activated RhoA and Rac-1 and led via TGFβ to apoptosis and a switch of the cells into a more
mesenchymal  phenotype,  as  evident  from  loss  of  WT-1  and  nephrin  and  induction  of  α-SMA  and  fibronectin
expression. Rac-1 and ROCK inhibition as well as blockade of TGFβ dramatically attenuated all these responses.
This suggests that Rac-1 and RhoA are mediators of podocyte dysfunction in CKD. Inhibition of Rho-GTPases may
be a novel approach for the treatment of CKD.
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Chronic  renal  failure  is  a  self-perpetuating  process  of
different etiology, which may ultimately lead to end-stage renal
failure  and  renal  replacement  therapy.  Numerous  conditions
such  as  diabetes  mellitus,  hypertension,  glomerulonephritis
and  preexistent  structural  renal  abnormalities  can  initiate
chronic  kidney  disease.  However,  once  the  disease  has
become  established  it  tends  to  progress  to  terminal  renal
failure  even  if  the  condition  that  initiated  the  process  was
successfully treated [1,2].
The  mechanisms  operative  in  progressive  chronic  renal
failure are incompletely understood and numerous processes
are considered relevant to mediate the different aspects of the
disease.  Glomerula  damage  is  frequently  observed  which
involves  podocyte  loss,  proliferation  of  mesangial  cells  and
thickening of the basal lamina. Also tubulo-interstitial fibrosis is
commonly  present  with  increased  inflammatory  activation  of
the  renal  tissue  and  deposition  of  matrix.  Ultimately,  these
processes  result  in  loss  of  active  nephrons  so  that  the
remaining  nephrons  including  their  glomeruli  undergo
compensatory hypertrophy [2,3].
Interestingly,  the  process  inducing  the  compensatory
hypertrophy of glomerula and even the whole kidney are not
well  understood.  Humoral  factors  like  neuropeptide  Y,
vasoactive peptides or lipids that accumulate in the blood are
discussed but also hydrostatic effects are considered being of
relevance.  Indeed,  it  is  widely  believed  that  chronic  kidney
disease  induces  glomerula  hypertension  which  then  further
progresses renal disease [3].
The transglomerular pressure gradient of the healthy kidney
is  30-40  mmHg  and  may  exceed  60  mmHg  in  the  diseased
kidney  [3].  Obviously,  such  a  pronounced  increase  in
hydrostatic  pressure  results  in  a  significant  increase  in
circumferential  cellular  strain  [4].  This  increased  mechanical
stress induces cellular activation and podocyte injury resulting
again in the final common pathway of end-stage renal failure
[5].  Podocytes  as  specialized  epithelial  cells  attached  to  the
glomerular basement membrane (GBM) are an essential part
of  the  glomerular  filter  barrier  preventing  the  loss  of  serum
proteins into urine. Glomerulosclerosis associated with massive
proteinuria is closely related to specific structural changes in
podocyte  complex  architecture  [6].  Notably,  even  small
rearrangements of actin cytoskeleton result in effacement and
disappearance of podocyte actin-rich foot processes [7]. These
events represent early manifestations of progressive podocyte
damage associated with detachment of podocytes from GBM
and their irreversible loss. Depletion of podocytes goes in line
with a robust increase in apoptosis due to activation of TGFβ
signaling pathway [8]. TGFβ secreted by mesangial cells and
potentially by podocytes themselves binds to its receptors on
podocyte  surface  and  initiates  impairment  of  podocyte
adhesion [9]. Another mechanism contributing to the reduction
in  podocyte  number  is  activation  of  local  tissue  angiotensin
system  in  podocytes  in  response  to  mechanical  stress  [10].
The increased capillary wall tension is transmitted to podocytes
through cell-matrix contacts. Specific components of GBM are
therefore  of  great  importance  for  proper  interaction  with
adhesion receptors localized on podocyte foot processes [11].
On the other hand, variations in GBM protein composition or
their presence in the soluble form might affect cellular response
to stretch [12].
Rho family small GTPases are known powerful regulators of
actin cytoskeletal dynamics, cell adhesive interactions, motility,
or cell polarity [13]. However, small GTPases also control other
important  cellular  functions  such  as  gene  expression,
proliferation, cell adhesion, and apoptosis [14]. Although Rac-1
and  RhoA  are  needed  for  normal  cellular  function,  over-
activation  of  the  proteins  for  example  in  response  to
angiotensin II (AngII) contributes to disease processes in the
vascular  but  also  renal  system.  Interestingly,  HMG-CoA-
reductase  inhibitors  (statin),  if  given  at  high  concentrations,
may  in  part  inhibit  Rac-1  and  RhoA  activity  [15].  Statins
decrease  the  formation  of  isoprenoids,  intermediates  of  the
cholesterol de novo synthesis, and isoprenoids are required to
tether  Rac-1  and  RhoA  to  the  plasma  membrane.  Some
evidence has been presented that statins delay the progression
of chronic renal failure but it is unknown whether this is due to
an inhibition of small GTPases [16]. Moreover, it is not known
whether Rac-1, which activates the NADPH oxidase and elicits
oxidative  stress,  or  RhoA,  which  for  example  decreases  NO
synthase  expression  and  induces  inflammation  is  the  main
driver of GTPase-dependent progression of renal disease [15].
On  such  basis,  we  determined  the  impact  of  inhibitors  of
Rac-1  and  of  RhoA-dependent  kinase  (ROCK),  the  most
important downstream kinase of RhoA, in a murine model of
chronic  progressive  renal  failure.  We  compared  their
effectiveness  to  statins  and  the  gold  standard  of  treatment,
ACE inhibition. Further, we analyzed the contribution of both
small  GTPases  to  podocyte  function  focusing  on  effects  of
mechanical stress.
Results
Rac-1 and ROCK inhibition protects kidney function in
vivo
To investigate the contribution of the small GTPases Rac-1
and  RhoA  to  the  processes  leading  to  progressive  chronic
renal  failure,  the  5/6Nx  mice  and  their  sham  operated
counterparts  were  treated  with  a  set  of  inhibitors:  the  HMG-
CoA  reductase  inhibitor  Rosuvastatin,  the  ACE  inhibitor
Ramipril,  the  Rac-1  inhibitor  EHT1864  and  the  ROCK  (a
downstream  protein  kinase  of  Rho)  inhibitor  SAR407899.  As
judged  by  blood  urea  nitrogen  and  plasma  creatinine,  5/6Nx
induced  chronic  renal  failure,  and  these  values  were
significantly lower in all groups receiving treatment (Figure S1).
With the exception of the statin, all compounds attenuated the
development of albuminuria in response to 5/6Nx at 4 weeks
post  op  and  this  protective  effect  persisted  until  the  end  of
experiment at 8 weeks. ACE inhibition was superior to Rac-1 or
ROCK  inhibition  in  preventing  albuminuria  but  co-
administration  of  the  ROCK  inhibitor  to  the  ACE  inhibitor
exerted  a  significant  add  on  protective  effect  after  8  weeks
(Figure 1A&B).
Hypertension  is  considered  a  main  driver  of  the  disease
process in the 5/6Nx model and indeed, mice became overtly
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inhibition prevented hypertension development throughout the
experiment. The other compounds, however, had no effect on
blood pressure (Figure 1C&D) suggesting that the protective
effect of Rac-1 and ROCK inhibition is pressure independent
and consequence of structural preservation of the glomerulum.
Indeed,  pronounced  glomerulosclerosis  was  present  in
glomeruli  of  5/6Nx  mice  without  treatment  and  this  was
attenuated  by  Rac-1  and  ROCK  inhibition  as  demonstrated
with the PAS staining. Also the ACE inhibitor was effective in
partially maintaining glomerula architecture although we cannot
discriminate whether this was consequence of lower glomerula
hypertension or of the blockade of the deteriorating effects of
AngII directly in the glomerulum (Figure 2A&B). Interestingly,
although  incapable  of  preventing  proteinuria,  statin-treatment
effectively  attenuated  glomerulosclerosis  development,
reiterating  that  already  minor  structural  changes  of  the
glomerulus are sufficient to induce gross proteinuria. The cell of
glomerulus  most  sensitive  to  structural  alteration  is  the
podocyte. Staining for the specific markers podocin and WT-1
revealed that glomeruli from remnant kidneys were depleted of
podocytes. Treatment with any of the compounds used in the
Figure  1.    Effect  of  GTPase  inhibition  of  5/6  nephrectomy  (Nx)-induced  renal  albumin  excretion  and
hypertension.  Albuminuria 4 weeks (A) and 8 weeks (B) and blood pressure 4 weeks (C) and 8 weeks (D) after induction of 5/6Nx.
Data are means ± SEM. *P<0.05 vs. corresponding sham control (n=5-10 for sham and n=6-17 for 5/6Nx mice); # P<0.05 vs. 5/6Nx
control (n=6-13); § P<0.05 vs. 5/6Nx + ACE (n=8-13). Ctrl: control. EHT: Rac-inhibitor EHT1864, SAR: ROCK inhibitor SAR407899,
Stat: HMG-CoA reductase inhibitor Rosuvastatin, ACE: ACE inhibitor ramipril.
doi: 10.1371/journal.pone.0080328.g001
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2A&C&D),  and  again,  the  statin  exerted  the  weakest  effect
(Figure  2D).Tubular  injury  and  renal  fibrosis  are  often
secondary to glomerula disease. Indeed, the scores for these
afflictions  recapitulated  the  glomerulosclerosis  index  (Figure
S2).
Expression pattern of TGFβ, a master profibrotic cytokine, as
determined  by  RT-PCR  from  renal  cortex,  confirmed  the
histological  findings.  Its  disease-induced  overexpression  was
attenuated  in  kidneys  from  mice  treated  with  any  of  the
inhibitors  applied  to  a  similar  extent  (Figure  3A).  Similar
patterns were observed in expression of two fibrosis indicators;
fibronectin  and  α  -SMA  (Figure  3A).  These  observations
Figure 2.  GTPase inhibition attenuates 5/6Nx-induced renal histological changes.  Representative PAS (left panel; scale bar
100 µm) and podocin (right panel;, brown color, scale bar 20 µm) stained kidney sections (A), glomerulosclerosis index (B), podocin
staining quantification (C), and percentage of WT-1 positive stained glomeruli (D) in kidneys from sham and 5/6Nx mice non-treated
or treated with EHT, SAR, statin and ACE inhibitors. Data represent means ± SEM. *P<0.05 vs. corresponding sham control (n=5-7
for sham and n=8-18 for 5/6Nx mice); # P<0.05 vs. 5/6Nx non-treated mice (n=9-18).
doi: 10.1371/journal.pone.0080328.g002
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fibrosis in response to 5/6Nx.
Rac-1 and ROCK inhibition reduces podocyte injury in
vivo
Although  the  disease  condition  studied  here  in  particular
affects glomeruli, the RT-PCR results are primarily a reflection
Figure 3.  GTPase inhibition prevents 5/6Nx-induced renal fibrosis.  RT-PCR analysis of renal TGFβ, fibronectin and smooth
muscle α-actin (α -SMA) expression (A), and expression of podocyte specific markers podocin, nephrin and WT-1 (B) detected in
renal cortex homogenates. Polymerase 2a (Polr2a) served as housekeeping gene. Data are expressed as mean ± SEM from four
mice of each group. *P<0.05 vs. corresponding sham control; # P<0.05 vs. 5/6Nx control.
doi: 10.1371/journal.pone.0080328.g003
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which  is  more  abundant  in  the  renal  cortex.  Although  this
aspect  is  a  limitation  of  our  study  and  studies  on  isolated
glomeruli  would  have  been  desirable,  RT-PCR  for  specific
podocyte  markers  confirmed  the  data  obtained  by  histology:
The  mRNA  expression  of  podocin,  nephrin,  and  WT-1  was
dramatically  reduced  after  5/6Nx  compared  to  WT  controls.
Statin treatment as well as Rac-1 or ROCK inhibition prevented
the loss of podocyte marker expression in response to 5/6Nx
(Figure 3B). Interestingly, ACE inhibitor only prevented the loss
of WT-1 mRNA expression, whereas the loss of nephrin and
podocin  mRNA  expression  in  response  to  5/6Nx  was  not
affected by ACE inhibition. Although this finding is interesting, it
might  be  due  to  secondary  changes  induced  by  the  ACE
inhibitor and is unlikely to indicate that the compound failed to
protect podocytes.
Inhibition of Rac-1 and ROCK prevents stretch-induced
epithelio-mesenchymal phenotype switch of cultured
podocytes
To  further  investigate  the  mechanism  underlying  the
protective role of Rac-1 and ROCK inhibition in chronic renal
failure  we  performed  cell  culture  experiments  in  murine
podocytes. As our in vivo studies were based on mouse on the
SV129 genetic background, we isolated glomeruli from kidneys
of  this  strain  to  obtain  podocyte  culture.  Isolated  primary
podocytes  expressed  podocyte-specific  proteins  like  WT-1,
nephrin,  and  synaptopodin  but  not  the  smooth-muscle  cell
marker  α  -SMA  (Figure  4A;  Figure  S3).  To  simulate  the
glomerula  hypertension-induced  increase  in  pressure,
podocytes were exposed to static stretch in the Flexcell device
(15% elongation). Mechanical strain increased activity of both
Rac-1  and  RhoA,  as  determined  by  G-LISA.  Interestingly,
ROCK  inhibition  as  well  as  Rac-1  inhibition  prevented  the
stretch-induced  increase  in  GTPase  activity  (Figure  4B&C).
Given that ROCK is down-stream of RhoA and that EHT1864 is
specific  for  Rac-GEFs  this  observation  demonstrates  that
sensing  of  mechanical  load  leading  to  GTPase  activation
requires  an  active  cytoskeleton.  Indeed,  podocytes  under
stretch  condition  underwent  strong  actin  polymerization  and
this was attenuated by Rac1 and ROCK inhibition (Figure 4D).
Given the activation of GTPase, we infer that stretch leads to
podocyte  activation  and  initiates  podocyte  dedifferentiation.
Indeed,  mechanical  stretch  enhanced  the  expression  of
fibronectin and α -SMA in podocytes and both, the induction of
mRNA and protein of fibronectin and α -SMA were prevented
by  Rac-1  and  ROCK  inhibition  (Figure  5A-D).  Podocyte
dedifferentiation  was  as  well  accompanied  by  a  loss  of  the
podocyte-specific  markers  nephrin  and  WT-1  and  also  these
changes were prevented by Rac-1 and ROCK inhibition (Figure
5E&F).
TGFβ mediates stretch-induced podocyte activation
One of the strongest cytokines promoting fibrotic processes
is TGFβ. TGFβ stimulates matrix production, induces epithelial
cell apoptosis and induces epithelio-mesenchymal phenotype
switch. On such a basis we determined a potential involvement
of  TGFβ  in  stretch-induced  podocyte  signaling.  Stretch
increased  TGFβ  mRNA  and  protein  expression  in  podocytes
via a pathway sensitive to Rac1 and ROCK inhibition (Figure
6A&B). Also down-stream TGFβ signaling required the small
GTPases. Recombinant TGFβ induced fibronectin expression
(Figure 6C&D) and podocyte apoptosis (Figure 6E&F) and also
these processes were sensitive to the inhibition of Rac1 and
ROCK.  We  therefore  hypothesized  that  also  the  stretch-
mediated  induction  of  fibronectin  may  involve  TGFβ.  Indeed,
application of a TGFβ neutralizing antibody prevented stretch-
induced fibronectin deposition (Figure 7A&B). In line with this,
prolonged  stretch  induced  podocyte  apoptosis  and  also  this
could be blocked by the inhibition of Rac1 and RhoA (Figure
7C&D).
Discussion
In the present study we determined the impact of Rac-1 and
ROCK inhibition on the progression of chronic renal failure in
mice  and  on  stretch-induced  phenotype  switch  in  cultured
murine  podocytes.  In  vivo,  inhibition  of  Rac-1  and  ROCK
attenuated  structural  remodeling  and  albuminuria  in  a
pressure-independent manner. In cultured podocytes subjected
to  static  strain,  small  GTPases  were  identified  as  important
mediators  of  podocyte  activation  which  were  involved  in
stretch-induced  TGFβ  induction  and  down-stream  TGFβ
signaling.
Increased glomerular pressure is an important factor known
to cause podocyte injury [17]. Intraglomerular hypertension and
hyperfiltration develop during chronic renal failure, in part as a
consequence  of  altered  autoregulation  of  the  glomerular
microcirculation involving vasodilatation of afferent and efferent
arteriole  [18].  Current  clinical  strategies  in  slowing  the
progression  of  chronic  kidney  disease  mainly  involve  ACE
inhibitors  and  AT1  receptor  blockers  [19].  These  prevent
glomerular hypertension by a vasodilator effect on the efferent
arteriole. Moreover, ACE inhibitors attenuate the inflammatory
response during chronic renal failure by preventing local AngII
production. By this mechanism they mitigate structural changes
and  attenuate  dedifferentiation  [20].  In  the  present  study  we
were able to confirm the reno-protective effect of ACE inhibition
in  the  5/6Nx  model  and  also  observed  a  pronounced  anti-
hypertensive effect of the compound. Nevertheless, we did not
measure  intraglomerular  pressure,  which  represents  a  major
limitation of the present study as systemic blood pressure is not
an indicator of glomerular hypertension. With the exception of
the ACE inhibitor, none of the compounds affected systemic
blood  pressure,  but  they  still  might  have  lowered
intraglomerular pressure and by that aspect delayed disease
progression.
Although  ACE  inhibitors  are  successful  in  delaying  the
progression of chronic renal failure, few alternative treatment
options exist and thus there is great medical need for novel
strategies combating this disease [2]. Modulating Rho-GTPase
signaling might be one of these: RhoGTPases affect different
renal cells [21-23] and their activation is thought to contribute to
renal  injury  [24,25].  Rho  kinase  has  been  implicated  in  cell
proliferation,  migration  and  apoptosis  as  well  as  matrix
deposition [26], which makes it an attractive candidate altering
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PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e80328Figure 4.  Stretch increases Rac-1 and RhoA activity in murine podocytes.  Expression of the podocyte proteins WT-1, nephrin
and synaptopodin as well as smooth muscle α-actin in podocytes and rat smooth-muscle cells (A). Activation of Rac-1 (B) and
RhoA (C) in primary podocytes in response to stretch (1h) with or without preincubation with EHT (1µM) or SAR (1µM). Data are
means ± SEM. *P<0.05 vs. corresponding non-stretched control; # P<0.05 vs. stretched control (n=3 for Rac-1 assay and n=5 for
RhoA assay). Phalloidin staining of the actin cytoskeleton in podocytes after 24-hour stretch with or without EHT (1µM) or SAR
(1µM) treatment (D).
doi: 10.1371/journal.pone.0080328.g004
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PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e80328Figure 5.  Stretch-induced signaling is sensitive to GTPase inhibition.  Effect of stretch (24hours) on podocytes in the presence
or  absence  of  EHT  (1µM)  or  SAR  (1µM)  on  fibronectin  mRNA  expression  (A),  α-smooth  muscle  actin  mRNA  expression  (B)
fibronectin protein expression (C&D) and nephrin and WT-1 mRNA expression (E&F). ERK was used as reference for protein
expression,  polymerase  2a  (Polr2a)  as  housekeeping  gene  for  mRNA  expression.  Data  represent  the  mean  ±  SEM  of  three
independent experiments. *P<0.05 vs. corresponding non-stretched control; # P<0.05 vs. stretched control.
doi: 10.1371/journal.pone.0080328.g005
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PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e80328Figure 6.  TGFβ-induced podocyte signaling involves small GTPases.  RT-PCR for TGFβ (A) in podocytes with and without
exposure to stretch (24hours) in the absence or presence EHT (1µM) or SAR (1µM). (B) TGFβ protein expression detected by
ELISA in podocytes with and without exposure to stretch (24hours) and treated with or without EHT (1µM) or SAR (1µM). Western
blot for fibronectin (FN) (C) and quantification (D) produced by primary podocytes stimulated with or without TGFβ (10 ng/ml), in the
absence or presence of EHT (1µM) or SAR (1µM). Annexin V staining after exposure with or without TGFβ (24h) (E) and its
quantification  (F)  in  podocytes  treated  with  or  without  EHT  (1µM)  or  SAR  (1µM).  Data  represent  the  mean  ±  SEM  of  three
independent experiments. *P<0.05 vs. corresponding non-stretched control (A, B) or non-stimulated control (D, F); # P<0.05 vs.
stretched control (A, B) or TGFβ stimulated control (D, F).
doi: 10.1371/journal.pone.0080328.g006
RhoGTPase in Chronic Kidney Disease
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e80328differentiating processes. ROCK inhibition with Fasudil reduced
the trace albuminuria in STZ-diabetic rats [27]. Similar results
were  obtained  in  a  rat  model  of  accelerated  kidney  disease
(combination of STZ-diabetes and unilateral nephrectomy) [28].
Importantly, prolonged treatment with Fasudil also did not lower
blood  pressure  in  rats.  Similar  results  were  obtained  in
spontaneously hypertensive rats subjected to 5/6Nx [29]. Also
in this model, Fasudil reduced albuminuria in a blood pressure-
independent manner. Despite this, Fasudil has been criticized
for limited specificity towards Rho kinase [30] and thus some of
the effects currently attributed to ROCK inhibition by Fasudil
might  be  mediated  by  protein  kinase  A  or  protein  kinase  C
inhibition. On such a basis, we determined whether the highly
specific ROCK inhibitor SAR407899 [31] elicits protection in the
murine remnant kidney model. Previous observations indicated
that SAR407899 has pressure-independent effects similar as
Fasudil:  It  reduced  migration  of  a  monocyte  cell  line  and
attenuated  PDGF-induced  smooth  muscle  cell  proliferation
[31].  Indeed,  we  here  observed  that  also  specific  ROCK
inhibition attenuated progression of renal failure in mice. Given
that mechanistically, ACE inhibitors and ROCK inhibitors act on
different pathways to prevent renal disease, we determined the
impact of combined application of Ramipril and SAR407899 on
albuminuria,  the  most  sensitive  parameter  of  glomerula
dysfunction. Importantly, ROCK inhibition conferred additional
protection  on  top  of  ACE  inhibition.  This  observation  is  very
Figure 7.  TGFβ mediates stretch-induced signaling in podocytes.  Western blot for fibronectin (FN) (A) and quantification (B)
of primary podocytes with and without stretch exposure in the absence or presence of anti-TGFβ neutralizing antibody (40 µg/ml).
Annexin V activation (G) and its quantification (H) in podocytes with and without stretch-exposure treated with or without EHT (1µM)
or SAR (1µM). The data shown are representative of three independent experiments and are means ± SEM (B, D). *P<0.05 vs.
corresponding non-stretched control; # P<0.05 vs. stretched control.
doi: 10.1371/journal.pone.0080328.g007
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experiencing  disease  progression  under  ACE  inhibitor
treatment. Additional studies therefore should be undertaken to
test  whether  our  observation  can  be  translated  into  other
preclinical models of chronic kidney disease.
As a second GTPase-dependent mechanism, we focused on
Rac-1. This protein also belongs to the Rho family of GTPases
but differs from RhoA in its down-stream targets like NADPH
oxidase and p21-PAK [15]. Rac-1 is required for cell migration
as it is involved in lamellipodia formation and thus inhibition of
this GTPase reduces inflammatory cell accumulation. Rac-1 is
also involved in NADPH oxidase activation and thus inhibition
of  Rac-1  reduces  oxidative  damage.  For  renal  cells,  it  was
shown  that  the  Rac-1  inhibitor  NSC23766  blocks  oxalate-
induced  NADPH  oxidase-mediated  oxidative  cell  injury  in
tubular  cells  [32].  In  vivo  NSC23766  reduced  the
hyperinflammatory response and barrier dysfunction of the lung
after  LPS-treatment  [33].  It  also  attenuated  lung  and  gland
damage in the cerulein-induced pancreatitis [34]. Interestingly,
inhibition  of  Rac-1  by  NSC23766  attenuated  neuronal  cell
apoptosis in response to ischemia by preventing JNK activation
[35]  providing  a  potential  explanation  for  the  anti-apoptotic
effect of EHT1864.
Recently,  EHT1864,  the  Rac-1  inhibitor  also  used  in  the
present  study,  was  tested  in  the  angiotensin  II-salt-induced
kidney injury model of double transgenic Tsukuba hypertensive
mice. Similarly as in the present study, EHT1864 attenutated
renal injury and fibrosis without affecting blood pressure [36]. In
salt-sensitive Dahl rats, also NSC23766 attenuated proteinuria
by  a  pathway  involving  the  mineralocorticoid  receptor.  As
NSC23766,  however,  also  effectively  lowered  the  blood
pressure in Dahl rats, it is unclear whether this was a simple
pressure-dependent  effect  [37].  Both  models  differ
considerably from the one used in the present study: Not only
that they focus on a very specific disease entity, they heavily
rely on oxidative stress and aldosterone and its signaling via
the mineralocorticoid receptor.
In  our  mechanistic  analysis  we  focused  on  the  aspect  of
podocyte injury and identified a novel role of Rac-1 in TGFβ
signaling.  TGFβ  can  activate  Rac-1  in  mesenchymal  cells
through  PAK2  [38].  Although  we  observed  that  inhibition  of
Rac-1  blocked  TGFβ-induced  Rac-1  activation,  the  signal
transduction from TGFβ to Rac-1 is unclear as the epithelial
enriched  proteins  Erbin  and  Merlin  usually  prevent  TGFβ-
mediated Rac-1 activation [39]. Whether or not this pathway is
operative in podocytes is not known. TGFβ is an established
driver of phenotype switch [40]. In response to high glucose in
immortalized  mouse  podocytes  the  process  could  be
attenuated by siRNA directed against Rac-1 [41].
The activity of Rac-1 and RhoA, the upstream activator of
ROCK  is  dependent  on  geranylgeranylation  of  the  small
GTPase.  This  tethers  the  protein  to  the  membrane  where  it
interacts  with  its  upstream  and  down-stream  effectors.  High
concentrations  of  statins  are  therefore  effective  in  reducing
Rho-GTPase  activation  [15].  Indeed,  we  observed  that
Rosuvastatin similar as SAR407899 and EHT1864 attenuated
the  structural  remodeling  in  response  to  5/6Nx.  Surprisingly,
Rosuvastatin  had  no  effect  on  albuminuria,  although  the
compound  reduced  albuminuria  in  the  rat  remnant  kidney
model [42]. To our knowledge, the present study is the first to
explore statin treatment in the murine remnant kidney model.
Thus  specific  conditions  applying  to  the  murine  system  may
therefore  underlie  their  lack  of  effect.  The  remnant  kidney
model is rarely used in mice as only certain strains, like SV129,
develop albuminuria and progressive renal failure [43]. On the
other hand, Rosuvastatin treatment was the least effective in
prevention of podocyte loss in our study and left a substantial
amount  of  podocyte-free  glomeruli  in  the  remnant  kidneys.
Despite  this,  also  in  another  study  Rosuvastatin  applied  to
ApoE-/- mice failed to reduce albuminuria [44] but in that study,
albuminuria was anyway very discrete.
Chronic kidney disease is an exceedingly complex process
which  affects  basically  every  cell  in  the  kidney  and  thus  a
comprehensive characterization of renal changes occurring in
the  disease  process  is  a  demanding  task.  Ideally,
determination of glomerula filtration rate, plasma lipids, electron
microscopy and a separate analysis of the changes occurring
in the glomerula and tubule fraction should be carried out in
addition to the measurements performed in the present study.
These important analyses, however, have not been carried out
in the present study which represents major limitations.
Of the cells contributing to chronic renal failure, podocytes
recently  gained  a  lot  of  interest  as  they  form  essential
components  of  the  filtration  barrier  and  as  proteinuria  after
barrier breakdown drives interstitial and tubular changes [40].
Numerous humoral factors, in particular angiotensin II but also
NPY, contribute to podocyte activation in chronic renal failure
[45] but also the mechanical environment changes. Given their
exceedingly  complex  structure  even  minor  changes  in
transglomerular hydrostatic pressure will result in activation of
podocyte  stretch  signals.  The  cytoskeleton  is  essential  for
mechanosensing as the tensegrity structure of actin is required
to establish points for force development and perception. As
RhoGTPases control actin dynamics they are both required for
mechanosensing and effectors of mechanosensing. Indeed, we
observed that static strain increases RhoA and Rac-1 activity
and  previously  it  noted  that  stretch,  albeit  applied  as  cyclic
stretch, leads to ROCK inhibitor-sensitive stress fiber formation
in  podocytes  [46].  Stretch  then  leads  to  compensatory  cell
contraction followed by spreading as well as activation of gene
expression. The latter aspect was evidenced by an induction of
TGFβ  and  an  increase  in  matrix  synthesis  and  was  also
sensitive  to  GTPase  inhibition.  Previously,  it  was  noted  in
conditionally  immortalized  mouse  podocytes  that  stretch
increases TGFβ and AT1 receptor expression and the remnant
kidney model exhibited similar features as stretch in vivo [10].
Although we focused on TGFβ in the present study, an intense
crosstalk to the AngII system was documented previously. For
example,  the  stretch-induced  activation  of  TGFβ  is  in  part
mediated  by  reactive  oxygen  species  (ROS)  formation
stimulated by the AngII system [40]. Rac1 is required for AngII-
induced  ROS  formation.  Therefore,  it  is  conceivable  that
stretch-induced  matrix  induction  mediated  through  TGFβ  not
only depends on RhoA to stabilize that cytoskeleton but also on
Rac1.
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apoptosis  [10]  and  also  TGFβ  is  known  to  induce  podocyte
apoptosis  [8].  The  degree  of  stretch  applied  in  the  present
study was rather moderate and thus it is conceivable that not
direct  cell  damage  but  stimulation  of  TGFβ  signaling  was
involved.  The  mechanisms  linking  GTPases  and  podocyte
apoptosis  have  not  been  explored.  Nevertheless,  numerous
reports  in  other  cell  types  document  that  inhibition  of  ROCK
[47,48] or Rac-1 [35,49] has anti-apoptotic effects.
In conclusion, in the present study we have demonstrated
that inhibition of Rac1 as well as of ROCK is an effective novel
approach  to  delay  the  progress  of  disease  in  the  murine
remnant  kidney  model.  As  underlying  mechanism  we
demonstrate that the inhibitors prevent strain-induced, TGFβ-
mediated apoptosis and phenotype switch of podocytes.
Materials and Methods
Animals
Male  SV129  mice  were  purchased  from  Harlan  (Borchen,
Germany). All experiments were initiated at a mouse age of 8-
weeks.  Animals  were  housed  in  an  SPF  facility  with  12/12
hours day/night cycle and free access to chow and water. Body
weight was monitored at least at the beginning and at the end
of  the  experiments.  5/6  nephrectomy  was  performed  under
isoflurane / buprenorphine anesthesia as previously described
with  some  modifications  [43]  and  all  efforts  were  made  to
minimize suffering. Briefly, left dorsal longitudinal incision was
performed to expose the left kidney. The upper branch of the
left renal artery was ligated by 6-0 prolene suture to produce
about  one  third  area  with  visible  renal  ischemia  infarct;  the
lower pole of the left kidney (about one third kidney size) was
removed by cautering. After 7 days of recovery, the right kidney
was  exposed  in  a  similar  preparation  and  removed  after
decapsulation  and  ligation  of  the  vessels  and  the  ureter  to
induce  a  total  5/6  nephrectomy  .  The  control  animals  were
sham operated in parallel by decapsulating the kidney. Early
mortality  within  the  first  3  days  was  approx.  20%.
Subsequently,  animals  were  randomized  to  the  treatment
groups.  The  substances  were  administered  as  follows:  The
statin  rosuvastatin  (final  concentration  50  mg/L),  the  ACE-
inhibitor  ramipril  (final  concentration  40  mg/L)  and  the  Rho
kinase inhibitor SAR 407899 (final concentration 50 mg/L) were
given with the drinking water, the Rac-1 inhibitor EHT 1864 (40
mg/kg) was given by intraperitoneal injection. SAR407899 [31]
and Ramipril were provided by Sanofi (Frankfurt). EHT 1864
was synthesized by the authors according to known methods in
literature  [50,51].  All  animal  experiments  were  conducted  in
accordance with the German Animal Protection Act and were
approved by the University Animal Care Committee as well as
Ethics  Review  Committee  for  laboratory  animals  of  District
Government  of  Darmstadt,  the  local  government  of  Hessen,
Germany, under the approval numbers F61/16 and F28/12.
Blood pressure measurements
Systolic blood pressure was assessed at 4 and 8 weeks after
the  initiation  of  treatment  by  an  automated  tail-cuff  Blood
Pressure Monitor (Visitech) in conscious, trained mice at room
temperature  as  reported  previously.  On  the  day  of  the
measurement, 20 recordings were registered and of them the
last 10 were used for data analysis [52].
Determination of plasma creatinine and urea
Plasma creatinine was determined by the HPLC system Elite
La Chrome VWR. An isocratic method was used with 15 mM
lithiumacetat  pH  4.7  /  methanol  (90:10  v/v).  The  cation
exchange column Hamilton PRP-X200 10 µm 4.1 x 150 mm
and a flow rate of 0.5 ml/min was used for chromatography.
Plasma  samples  (100  µl)  were  precipitated  with  100  µl
methanol (-20°C) and centrifuged for 10 min at 13,000 g by
4°C.  Supernatant  was  diluted  with  1  x  volume  of  15  mM
lithiumacetat  pH  4.7  and  30  µl  of  the  diluted  plasma  were
injected into the HPLC system. Detection was in UV mode at
234 nm. For measurement of urea level in plasma Urea Assay
Kit  (BioCat,  Heidelberg,  Germany)  was  used  following  the
manufacturer’s instruction.
Determination of urinary albumin and creatinine
Mice were placed in metabolic cages (Tecniplast) for 24-hour
urine collection. Urinary albumin excretion was determined by
ELISA  for  mouse  albumin  (Bethyl  Laboratories  Inc.,
Montgomery,  Texas)  and  urinary  creatinine  levels  were
estimated with the Creatinine assay kit (Labor-Technik, Berlin,
Germany) according to the manufacturer’s instruction.
Morphological Studies
Kidneys  were  perfused  with  phosphate-buffered  saline
(PBS),  subsequently  fixed  with  4%  paraformaldehyde/PBS
solution and embedded in paraffin. Renal sections (2 µm) were
deparaffinized  and  stained  with  haematoxylin/eosin  (HE),
periodic acid Schiff (PAS) and Sirius red (fibrous tissue stain).
The  sections  were  analyzed  for  parameters  as  reported
previously  [53]  by  investigator  blinded  to  the  study.  Matrix
accumulation  and  sclerosis  of  the  glomerular  tuft
(Glomerulosclerosis  index)  were  determined  in  PAS  and  HE
stained  sections  with  the  scoring  system  used:  0  –  normal
glomerulus; 1 – mesangial expansion or sclerosis involving up
to 25% of the glomerular tuft; 2 – sclerosis of 25 to 50%; 3 –
sclerosis of 50 to 75% and/or segmental extracapillary fibrosis
or  proliferation;  and  4  -  global  sclerosis  >75%,  global
extracapillary  fibrosis  or  complete  collapse  of  the  glomerular
tuft.  Tubular  atrophy,  dilatation,  interstitial  inflammation  and
interstitial  fibrosis  (Tubulointerstitial  damage  index)  were
determined in HE sections 10 fields per kidney were randomly
graded for tubulointerstitial damage at a magnification of 100x
using  a  similar  scoring  system  from  0-4:  0  –  normal
tubulointerstitial structure; 1 – lesions involving less than 25%
of  the  area;  2  –  lesions  affecting  25  to  50%;  3  –  lesions
involving more than 50% up to 75%: and 4 – tubulointerstitial
damage  of  almost  the  entire  area.  Sirius  red  stained  kidney
sections  were  graded  for  fibrosis  at  a  magnification  of  100x
using 10 randomly selected power fields and a similar scoring
system  from  0-4:  0  -  normal  slight  staining  of  the  basement
membrane; 1 - increased sirius red positive staining involving
less than 25% of the tubulointerstitial area; 2 - marked sirius
staining in 25 to 50%; 3 - sirius red staining involving more than
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the entire area.
Cell culture and stimulation
Primary podocytes were isolated as described before [54].
Briefly,  after  transcardiac  perfusion  with  8  x  107  inactivated
Dynabeads  (Dynabeads  M450  tosylactivated,  Dynal)
suspended  in  HBSS  medium  (Invitrogen),  the  kidneys  were
minced into 1 mm3 pieces. The kidney pieces were digested
with 1 mg/ml collagenase A (Calbiochem) in HBSS at 37°C for
30 minutes and subsequently gently pressed through a 100 µm
cell strainer using a flattened pestle. The filtrate was passed
through a new strainer, cell suspension was centrifuged at 200
x g for 5 minutes and pellet was resuspended in 5 ml of HBSS.
Glomeruli containing Dynabeads were gathered by a magnetic
particle  concentrator,  washed  three  times  with  HBSS  and
finally  were  cultured  in  podocyte  medium  consisting  of  1640
RPMI  supplemented  with  GlutaMAX  (Invitrogen),  10%  heat
inactivated fetal calf serum (Biochrom), 100 U/ml penicillin and
100 mg/ml streptomycin, 5 mmol/L HEPES (Sigma-Aldrich), 1
g/L non-essential amino acids, 1 mmol/L sodium pyruvate (all
PAA,  GE  healthcare),  10  mg/L  insulin-transferrin-sodium
selenite  supplement  (Roche)  at  37°C.  For  experiments,  cells
were kept in serum-free medium for 24 hours and then treated
with Rac-1 and ROCK inhibitors (1µM), TGFβ (10 ng/ml), or
15%  static  mechanical  strain  (Flexcell  machine,  Dunn)  for
indicated timepoints.
Immunohistochemistry
Cells were washed with PBS and fixed with 4% PFA for 20
minutes. After incubation with primary antibodies: anti-nephrin
(Acris),  anti-synaptopodin,  anti-WT  (both  Santa  Cruz
Biotechnology Inc.), anti-podocin, anti-a-SMA (both Sigma) or
anti-phalloidin  Alexa  Fluor  647  conjugated  (Invitrogen)
appropriate  secondary  antibody  was  used:  Alexa  Fluor  anti-
rabbit  488,  Alexa  Fluor  anti-goat  488,  and  Alexa  Fluor  anti-
mouse  488  (all  from  Invitrogen).  Nuclei  were  counterstained
with  DAPI.  Staining  patterns  were  analyzed  with  confocal
fluorescent microscopy (LSM Zeiss 510 meta). Kidney sections
were stained with anti-podocin (Sigma Aldrich) and anti-WT-1
(Santa  Cruz  Biotechnology  Inc.).  Negative  controls  for
immunostaining  included  either  the  omission  of  the  primary
antibody or substitution of the primary antibody with equivalent
concentrations  of  a  pre-immune  rabbit  IgG.  After  antigen
retrieval  using  a  pressure  cooker,  primary  antibodies  were
incubated  overnight  at  4°C,  specific  biotinylated  secondary
antibodies (all by Vector Lab.) were applied to tissue sections,
followed by peroxidase-conjugated Avidin D (Vector Lab.), and
color development with diaminobenzidine.
For each biopsy, at least 20 glomerular cross-sections for the
podocin staining and 50 glomerular cross-sections for the WT-1
staining were evaluated in a blinded fashion. Podocin staining
was graded semi quantitatively on a scale of 0 to 3 (0 = no
staining; 1 = podocin staining is strongly reduced; 2 = podocin
staining is reduced, 3 = normal podocin staining). The number
of  WT-1  positive  cells  is  determined  and  means  of  WT-1
positive cells per glomerular cross-section were calculated. In
addition,  the  percentage  of  glomerular  cross-sections  lacking
WT-1 positive cells were evaluated.
qRT-PCR
Total RNA was extracted with the RNA Mini Kit (Bio&Sell).
cDNA was prepared with SuperScript III Reverse Transcriptase
(Invitrogen)  and  random  hexamer  primers.  Semiquantitative
real-time PCR was performed with Fast Plus EvaGreen Master
Mix and ROX as reference dye (Biotium) in an Mx4000 cycler
(Stratagene) with primer sequences as follows: α -SMA forward
primer (5'-ACA GAG GCA CCA CTG AAC CCT AAG-3') and
reverse  primer  (5'-ACA  ATC  TCA  CGC  TCG  GCA  GTA
GTC-3');  fibronectin  forward  primer  (5'-ATG  CAC  CGA  TTG
TCA ACA GA-3') and reverse primer (5'-TGC CGC AAC TAC
TGT  GAT  TC-3');  TGFβ  forward  primer  (5'-TGA  CGT  CAC
TGG AGT TGT ACG G-3') and reverse primer (5'-GGT TCA
TGT CAT GGA TGG TGC-3'); nephrin forward primer (5'-GCA
TCA CTC TGC AGG TCA CCT TTC-3') and reverse primer (5'-
AGG  CCA  TCC  ATG  ACT  GTC  TCA  TCC-3');  synaptopodin
forward  primer  (5'-AGG  GAC  CAG  CCA  GAT  AGA  GCA
AAG-3')  and  reverse  primer  (5'-CAT  GGG  ACT  GCG  GGA
CAT TAT GTG-3'); podocin forward primer (5'-AAG TGC GGG
TGA TTG CTG CAG AAG-3') and reverse primer (5'-TGT GGA
CAG CGA CTG AAG AGT GTG-3'); and WT-1 forward primer
(5'-TCT TCC GAG GCA TTC AGG AT-3') and reverse primer
(5'-TGC  TGA  CCG  GAC  AAG  AGT  TG-3').  Relative
expressions  of  target  genes  were  normalized  to  polymerase
(RNA) II (DNA directed) polypeptide A (Polr2a) with the primer
pair  5'-CTC  GAA  ACC  AGG  ATG  ATC  TGA  CTC-3'  and  5'-
CAC  ACC  CAC  TTG  GTC  AAT  GGA  TAG-3',  analyzed  by
delta-delta-CT  method  and  are  given  as  ratio  compared  to
control experiments.
Annexin V assay
Cells were incubated with TGFβ or were stretched for 24h at
37°C. Subsequently, cells were washed with warm HT buffer
(137  mmol/L  NaCl,  2.7  mmol/L  KCl,  0.5  mmol/L  MgCl2,  1.8
mmol/L CaCl2, 5 mmol/L glucose, 0.36 mmol/L NaH2PO4, 10
mmol/L  HEPES,  pH  7.4)  and  Annexin  V-FLUOS  (Roche
Applied  Science)  was  added  following  instructions  of  the
manufacturer. DAPI was used to stain nuclei. Annexin-stained
cells were visualized by confocal fluorescent microscopy (LSM
Zeiss  510  meta)  with  the  488-nm  laser  line.  Alternatively,
Annexin V-FLUOS stained cells (3x105 cells/3.5 cm well) were
scraped in lysis buffer (137 mmol/L NaCl, 20 mmol/L Tris/HCl,
pH 8.0, 5 mmol/L EDTA, 10% glycerol, 1% Triton X-100) and
fluorescence intensity was quantified by excitation at 488 nm
and emission at 520 nm by a Victor 2 fluorescent microplate
reader (Perkin Elmer laboratories).
Rac and Rho GTPase activity assay
Active Rac-1 and RhoA were measured using G-LISA Rac-1
Activation  Assay  Biochem  kit  and  G-LISA  RhoA  Activation
Assay  Biochem  kit  (colorimetric  assay;  Cytoskeleton)  as
instructed by the manufacturer. The signal was measured at
490  nm  with  a  microplate  reader  (MRX,  Dynatech
Laboratories).  Results  were  expressed  as  fold  increase  in
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normalized to protein content.
Western blotting
Cells were lysed in buffer containing 50 mmol/L Tris/HCl, pH
7.5, 150 mmol/L NaCl, 10 mmol/L NaPPi, 20 mmol/L NaF, 1%
Triton  X-100,  2  mmol/L  ortho-vanadate,  10  nmol/L  okadeic
acid, 40 mg/L PMSF, supplemented with protease inhibitor mix
(antipain,  aprotinin,  leupeptin,  chymostatin,  pepstatin,  trypsin
inhibitor;  2  mg/ml  each;  all  from  AppliChem).  Tissue  lysates
were  prepared  by  mortaring  kidneys  in  liquid  nitrogen  and
dissolving  the  powder  in  the  same  lysis  buffer.  After
determination of protein concentration by Bradford assay equal
amounts  of  proteins  were  boiled  in  Laemmli  buffer  and
separated on a 10% acrylamide SDS-PAGE gel. After transfer
of proteins onto nitrocellulose membranes the following primary
antibodies  were  used:  anti-fibronectin  (Sigma-Aldrich),  ERK
(Cell  Signaling).  Secondary  fluorescent-coupled  antibodies
CF770  goat  anti-rabbit  IgG  (Biotium)  and  Alexa  Fluor  680
donkey  anti-mouse  IgG  (Invitrogen)  were  visualized  by  a
LICOR infrared laser scanner. Densitometry was done with the
Odyssey  package  and  results  were  normalized  to  total  ERK
content and data are given as mean ± SEM.
Statistical analysis
Data  are  given  as  means  ±  SEM  analyzed  by  paired  or
unpaired  t  test  or  analyses  of  variance  (ANOVA),  with  and
without  repeated  measurements,  followed  by  Fisher´s  LSD
post  hoc  test,  depending  on  the  experimental  design.
Differences were considered significant at a P value of <0.05.
Supporting Information
Figure  S1.    GTPase  inhibition  improves  renal  blood
filtration  dysfunction  induced  by  5/6Nx.  Concentration  of
urea (A) and creatinine (B) in plasma 8 weeks after induction of
5/6Nx.  Data  are  means  ±  SEM.  *P<0.05  vs.  corresponding
sham  control,  #  P<0.05  vs.  5/6Nx  control  (n=4  for  urea  and
n=4-12 for creatinine measurement).
(TIF)
Figure  S2.    GTPase  inhibition  attenuates  5/6Nx-induced
renal fibrosis. Tubulointerstitial damage index (A) and fibrosis
index (B) in non-treated sham and 5/6Nx mice or after 8 weeks
of  treatment.  Data  represent  means  ±  SEM.  *P<0.05  vs.
corresponding sham control (n=5-7 for sham and n=8-18 for
5/6Nx mice); # P<0.05 vs. 5/6Nx control (n=9-18).
(TIF)
Figure  S3.    Podocyte  characterization.  Isolated  podocytes
were characterized by expression of specific podocyte proteins
nephrin  (A)  and  WT-1  (B)  by  RT-PCR  compared  to  mouse
liver.  Results  are  representative  of  3  independent  isolations
and are means ± SEM.
(TIF)
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